Login to Your Account



BMS' $2.4B Grab Spotlights Platforms

Attention Shoppers: Antibody Prizes Not Limited to Medarex

By Jennifer Boggs


Friday, July 24, 2009
There's one less antibody player on the market now that Bristol-Myers Squibb Co. has staked a claim to Medarex Inc. in the form of a $2.4 billion buyout offer, leaving many to speculate on the next takeout target in the rapidly diminishing antibody platform space. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription